Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...
Finanical Reports
Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
China-based Sino Biopharmaceutical Ltd (HKG: 1177) released its 2024 financial report, recording revenues of RMB...
HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth
China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...
Medbanks Reports 2024 Financial Results Amid Business Reorganization
Sipai Health Technology Co., Ltd (HKG: 0314), known as Medbanks, released its 2024 financial report....
WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...
FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development
US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...
Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...
Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....
Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences
German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...
Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth
Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues...
Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way
German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7%...
Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars
Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...
BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...
Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...
Viatris Q4 and Full-Year Results Show Greater China Growth
US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...
Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues...
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...
Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY
Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...